A quarter of Americans are hesitant about a coronavirus vaccine - Reuters/Ipsos poll

Andrew Cummings
May 24, 2020

As per sources, the ICMR, in collaboration with Bharat Biotech, aims to start human trials of the Covid-19 vaccine by the end of this year. He says that all of the vaccines will need to go through large, Phase III trials before they become available, bringing their timelines close together.

Top White House health expert Anthony Fauci is confident that the United States could begin to roll out a coronavirus vaccine by December.

Preclinical testing of a vaccine against the coronavirus conducted by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Russian Health Ministry has shown good results, and human trials are expected to start by June 15, Director Alexander Gintsburg told Sputnik News Agency.

Between 100,000 and 150,000 people may be enrolled in the studies, said Dr. Larry Corey, a vaccine expert at the Fred Hutchinson Cancer Center in Seattle, who is helping to design the trials.

A phase-1 trial using a single dose of a vaccine (Ad5-nCoV) that uses a recombinant adenovirus type-5 vector that carries the genetic material that codes for spike glycoprotein of novel coronavirus was found to be safe, well-tolerated and able to generate immune responses against the virus.

Overall, 84 percent of respondents said vaccines for diseases such as measles are safe for both adults and children, suggesting that people hesitant to take a coronavirus vaccine might reconsider, depending on safety assurances they receive.

On the 18th of May, Moderna, a U.S. biotech firm has talked about the first data we got from a human trial.

Human testing begins with a small safety trial in healthy volunteers, followed by a larger study to find the right dose and get an early read on efficacy.

It will cost about $8 million to get a vaccine to market. Trials can be carried out overseas, including in Africa, where the virus has just started to spread, Collins said.

This week, pharmaceutical giant AstraZeneca said it had the capacity to make a billion doses of the Oxford vaccine, and had secured an agreement to produce at least 400 million doses.

Preparation for mass production of the vaccine is already underway in anticipation of the trial proving successful.

More than 100 vaccine candidates against SARS-CoV-2 are in development worldwide, with about 12 in human testing created to mainly evaluate safety. The Johnson & Johnson, Sanofi and Merck & Co vaccines are a month or two behind the top candidates and "may be added over the course of the summer" after early-stage human trials, Collins said.

Merck has not made any specific announcements on its vaccine program and declined to comment.

Side effect profiles may be particularly important to getting people to get vaccinated against coronavirus once one is available.

There are reasons to be optimistic over the cutting-edge mRNA vaccines being developed to end the COVID-19 pandemic, according to an expert in the field.

Many of them said they were concerned the vaccine would be riskier than the disease itself because development is moving so fast.

Other reports by iNewsToday